In the last three months, 11 analysts have published ratings on Molina Healthcare MOH, offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 1 | 2 | 6 | 2 | 0 |
Last 30D | 0 | 0 | 2 | 0 | 0 |
1M Ago | 0 | 1 | 1 | 2 | 0 |
2M Ago | 0 | 0 | 2 | 0 | 0 |
3M Ago | 1 | 1 | 1 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $425.18, a high estimate of $460.00, and a low estimate of $390.00. Marking an increase of 3.16%, the current average surpasses the previous average price target of $412.17.
Breaking Down Analyst Ratings: A Detailed Examination
A clear picture of Molina Healthcare's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Andrew Mok | Barclays | Lowers | Equal-Weight | $430.00 | $437.00 |
Scott Fidel | Stephens & Co. | Maintains | Equal-Weight | $390.00 | - |
Stephen Baxter | Wells Fargo | Lowers | Equal-Weight | $410.00 | $440.00 |
Sarah James | Cantor Fitzgerald | Maintains | Overweight | $406.00 | - |
Kevin Fischbeck | B of A Securities | Announces | Underperform | $439.00 | - |
Kevin Fischbeck | B of A Securities | Announces | Underperform | $439.00 | - |
Stephen Baxter | Wells Fargo | Raises | Equal-Weight | $440.00 | $420.00 |
Andrew Mok | Barclays | Announces | Equal-Weight | $437.00 | - |
David Macdonald | Truist Securities | Raises | Buy | $460.00 | $435.00 |
Stephen Baxter | Wells Fargo | Raises | Equal-Weight | $420.00 | $367.00 |
Sarah James | Cantor Fitzgerald | Raises | Overweight | $406.00 | $374.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Molina Healthcare. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Molina Healthcare compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Molina Healthcare's stock. This analysis reveals shifts in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Molina Healthcare's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Molina Healthcare analyst ratings.
All You Need to Know About Molina Healthcare
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
Key Indicators: Molina Healthcare's Financial Health
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Molina Healthcare showcased positive performance, achieving a revenue growth rate of 10.03% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Molina Healthcare's net margin is impressive, surpassing industry averages. With a net margin of 2.39%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Molina Healthcare's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.34% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Molina Healthcare's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.45% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Molina Healthcare's debt-to-equity ratio surpasses industry norms, standing at 0.57. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
What Are Analyst Ratings?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.